Zura Bio price target raised to $12 from $11 at Chardan
The Fly

Zura Bio price target raised to $12 from $11 at Chardan

Chardan analyst Daniil Gataulin raised the firm’s price target on Zura Bio (ZURA) to $12 from $11 and keeps a Buy rating on the shares following the Q3 report. The firm says tibulizumab’s Phase 2b in systemic sclerosis is on track for a Q4 initiation.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App